Verzenio (abemaciclib) Letter of Medical Necessity
Verzenio (abemaciclib) is the only CDK4/6 inhibitor approved for adjuvant therapy in high-risk HR+/HER2- early breast cancer. PA criteria differ between metastatic and adjuvant indications.
FDA-Approved Indications
- ● HR+/HER2- metastatic breast cancer
- ● HR+/HER2- node-positive high-risk early breast cancer (adjuvant)
Why Verzenio Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Receptor status missing
- 2. Adjuvant criteria not met
- 3. GI toxicity management plan not documented
What to Include in a Verzenio Letter of Medical Necessity
Document receptor status, stage, nodal status, recurrence risk, prior therapies, planned regimen, and monarchE eligibility criteria for adjuvant use.
Key clinical evidence to cite:
- ✓ MONARCH 1-3
- ✓ monarchE adjuvant trial
Relevant guidelines:
- 📖 NCCN Breast Cancer Guidelines
- 📖 ASCO Adjuvant Therapy Guidelines
Verzenio Prior Authorization Criteria
Standard criteria across major US payers for Verzenio. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Verzenio
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Verzenio Prior Authorization FAQ
Why was my Verzenio prior authorization denied?
The most common denial reasons for Verzenio are: Receptor status missing; Adjuvant criteria not met; GI toxicity management plan not documented.
What should a Verzenio Letter of Medical Necessity include?
Document receptor status, stage, nodal status, recurrence risk, prior therapies, planned regimen, and monarchE eligibility criteria for adjuvant use.
Which payers cover Verzenio?
Verzenio is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part D, though formulary tier and prior authorization criteria vary.